lilly
Lilly to cut 5,500 jobs in major restructuring
September 30, 2009Sales and Marketing lilly, restructure
Lilly’s chief executive has unveiled a major restructuring which will see it shed 5,500 jobs, helping to cut costs and …
Blow for Irish pharma sector as Teva, Elan cut staff
September 7, 2009Manufacturing and Production Elan, Teva, lilly
Ireland’s pharmaceutical sector suffered a double blow last week as two drugmakers opted to make staff redundant at manufacturing plants …
Effient approved in US
July 17, 2009Research and Development, Sales and Marketing Daiichi Sankyo, Effient, US, lilly
Lilly and Daaichi-Sankyo have gained US approval of their new blood clotting treatment Effient, but hopes of strong sales are …
US approval boosts Plavix competitor
July 14, 2009Research and Development, Sales and Marketing Effient, FDA, US, lilly
US regulator the FDA has approved Lilly and Daiichi Sankyo's Effient, a rival treatment to the world's best-selling blood-thinning drug …
Lilly invites researchers to submit novel compounds online
June 16, 2009Medical Communications, Research and Development digi, lilly
Lilly is launching a new web portal which it hopes will attract drug discovery researchers with promising new compounds. The …
Efient launched in the UK
April 9, 2009Research and Development, Sales and Marketing Daiichi, Effient, lilly
Lilly and Daiichi Sankyo's blood-thinning drug Efient has been launched in the UK for heart attack patients, taking on blockbuster …
Lilly forges risk-sharing R&D alliance with India’s Zydus
April 6, 2009Research and Development Asia, India, lilly
Eli Lilly has forged a research collaboration with India's Zydus Cadila that sees the two companies combine their efforts in …
Europe approves Lilly’s Plavix rival
February 25, 2009Research and Development, Sales and Marketing Daiichi, Effient, lilly
Lilly and Daiichi Sankyo have won European approval for their blood-thinning drug Efient, which will go up against established blockbuster …
Lilly to reduce pipeline costs by a third
December 17, 2008Research and Development lilly, restructure
Lilly aims to reduce the cost of it bringing new molecules to market by a third.The company's goal is to …
Companies try to quell rumours on prasugrel
October 17, 2008Sales and Marketing Efient, lilly
Daiichi-Sankyo and Lilly have responded to media speculation around the FDA's make-or-break ruling on their major new drug prasugrel. The …
Lilly eyes oncology focus with ImClone acquisition
October 9, 2008Sales and Marketing Cancer, MA, lilly
Lilly is to buy ImClone for $6.5 billion after outbidding Bristol-Myers Squibb for the biotech company. Lilly says the acquisition …
Long-acting Zyprexa gets green light
October 2, 2008Sales and Marketing lilly, psych
Lilly's Zypadhera has been recommended in Europe for use in stabilising schizophrenic patients who are already receiving treatment. The European …
Lilly unveils streamlined business structure
May 22, 2008Sales and Marketing lilly, restructure
A simplified and slimmed-down corporate structure has been unveiled by US pharmaceutical firm Lilly, which says it hopes to cut …
Lechleiter to be new Lilly chief
January 3, 2008Sales and Marketing lilly
John Lechleiter, Lilly's current president and chief operating officer has been named as the company's next chief executive.Sidney Taurel is …
New products behind Lilly growth
October 19, 2007Sales and Marketing lilly, zyprexa
Sales rose 19% for Lilly in the third quarter of the year, with depression treatment Cymbalta leading the growth in …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
